ClinicalTrials.gg
Not yet recruitingNCT07239271Updated Nov 20, 2025

A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model

A Phase 3 interventional study of The control group and Adaptive therapy of de-escalation and escalation based on imaging and molecular analysis for predicting response in Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Not yet recruiting. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 3, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 54 studies in Breast Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences — 36 open to participants now, 39 under way, 6 of them phase 3. Breast Neoplasms · Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Planned enrollment
4th of 41
2,000 · median 138
Started
2025
with 10 others
Phase 3
7 of 54
4 open now
Primary completion
2027-12
later than 18 of 38 live
Registered
49th of 54
by date

Among the 54 studies in Breast Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, this one is the 4th largest by planned enrollment of the 41 interventional ones that give a count, is one of 11 that started in 2025, is one of 7 in phase 3, reaches primary completion later than 18 of the 38 other live ones, and was the 49th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

36 of the 54 studies in Breast Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences are open now, in 1 country. Recruiting first, the newest first:

31 more — sign in →

By country, each count listing its studies:

All 36 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Breast Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, or all of them as a file.
02

Study summary

This study is a phase III clinical trial to explore the efficacy and safety of HER2-positive breast cancer neoadjuvant adaptive therapy compared with standard therapy based on multi-omics data, and to explore a new prediction model for pCR. The trial protocol in this study design has sufficient preliminary basis.

HER2-targeted therapies can significantly improve pCR rates and enhance clinical outcomes in HER2-positive breast cancer patients undergoing neoadjuvant treatment. However, standard neoadjuvant regimens typically involve multiple chemotherapeutic agents, often accompanied by severe adverse reactions. To optimize neoadjuvant strategies, minimize chemotherapy-related toxicities, and maximize the therapeutic advantages of anti-HER2 therapies, research on downstaging chemotherapy regimens has been intensively pursued. The first phase III HELEN-006 study evaluating the efficacy and safety of albumin-bound paclitaxel combined with neoadjuvant chemotherapy (nab-PHP) in HER2-positive breast cancer, led by Professor Liu Zhenzhen's team at Henan Cancer Hospital, was published online in The Lancet Oncology. This landmark study demonstrated that the nab-PHP regimen achieved higher pCR rates and better tolerability compared to the standard TCbHP regimen, charting a new course for downstaging chemotherapy approaches.

In recent years, new anti-HER2 drugs such as pyrotinib, T-DM1, and T-DXd have been continuously developed and launched, achieving good results in the treatment of HER2-positive breast cancer. These advances have changed clinical practice and are recommended in domestic and international guidelines for second-line or later-line treatment of advanced HER2-positive breast cancer. Their efficacy in neoadjuvant therapy is still being explored. The PHEDRA study is a multicenter, double-blind, randomized, controlled phase 3 trial that included a total of 355 patients: 178 in the group receiving docetaxel and trastuzumab combined with pyrotinib (TH+Py), and 177 in the group receiving docetaxel and trastuzumab combined with placebo. The study results show that the pCR rate in the TH+Py group was significantly higher than in the TH+placebo group (41.0% vs. 22.0%, P\<0.0001). The DESTINY-Breast 11 study is an open-label phase III clinical trial designed to investigate the efficacy and safety of neoadjuvant T-DXd monotherapy or T-DXd followed by sequential THP compared with dose-dense doxorubicin and cyclophosphamide followed by sequential THP (ddAC-THP) in patients with high-risk, early-stage HER2+ breast cancer. Patients with locally advanced HER2+ breast cancer, either HR+ or HR-, were randomized in a 1:1:1 ratio to Group A (T-DXd monotherapy), Group B (T-DXd followed by sequential THP), or Group C (ddAC-THP). The primary endpoint is pathological complete response (pCR). Currently, the DESTINY-Breast 011 study is still ongoing. At the 2024 SABCS conference, results were reported from a prospective, randomized, open-label phase II trial of SHR-A1811, a HER2-targeted antibody-drug conjugate, in the neoadjuvant treatment of HER2-positive early breast cancer. The main goal of this study is to assess the efficacy and safety of SHR-A1811 in the neoadjuvant treatment of HER2-positive early breast cancer. Open-label, phase II trial; the primary objective of this study is to explore the efficacy and safety of SHR-A1811 as neoadjuvant therapy in HER2-positive early-stage breast cancer. The pCR rate of SHR-A1811 monotherapy was 63.2% in the overall population, 50.0% in HR+ breast cancer, and 74.5% in HR- breast cancer. Everolimus is an mTOR inhibitor that can suppress the "phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR)" signaling pathway in tumor cells, thereby exerting an anti-cancer effect. In the BOLERO-3 clinical study, for patients with advanced disease who had failed anti-HER2 therapy, adding everolimus to vinorelbine plus trastuzumab prolonged the duration of disease control by about 1.2 months.

Our research group has previously established a nationwide multicenter multi-omics database that includes clinical information, pathological characteristics, and ctDNA data from 958 patients with advanced breast cancer. This has clarified the gene mutation profiles and prognostic features of advanced breast cancers with different molecular subtypes. Subsequently, we further developed a dynamic ctDNA monitoring sample library with 430 cases, tracking gene changes at multiple time points during the treatment of advanced breast cancer patients. By integrating clinical information, pathological features, and other multi-omics data, we comprehensively explored the process of tumor clonal evolution during treatment in patients with advanced breast cancer, providing a solid foundation for the development of efficacy prediction models.

This study is a nationwide, multicenter, prospective, randomized, controlled phase III clinical trial. It aims to compare the efficacy and safety of mu

03

Conditions studied

  • Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients aged 18-70 years;
  2. Performance Status (PS) score of 0-1;
  3. confirmed operable early or locally advanced invasive breast cancer, with a primary tumor diameter >2 cm;
  4. Patients with pathologically or cytologically confirmed primary breast cancer. For multifocal tumors (multiple tumors confined to the same quadrant as the primary tumor), it is recommended that all lesions be confirmed as -positive prior to enrollment;
  5. TNM stage II-IIIc (T2-3, N0-1, M0 or T2-3, N2-3, M0 or T4, any N, M0);
  6. Pathologically confirmed HER2 positivity: IHC result of 3+ or 2+/ISH+;
  7. Known status of estrogen receptor (ER), progesterone receptor (PgR), and Ki-67;
  8. The patient agrees to provide tumor tissue and blood samples as specified in the protocol;
  9. It is recommended that the patient's organ function meets the following requirements, as determined by the investigator based on each patient's condition:

    1. Complete blood count (no blood transfusion within the past 14 days): Neutrophils (ANC) ≥1.5×10⁹/L; (PLT) ≥100×10⁹/L; (Hb) ≥90 g/L; White blood cells (WBC) ≥2.5×10⁹/L;
    2. Blood biochemistry: Total (TBIL) ≤1.5 times the (ULN); for patients with Gilbert's syndrome, TBIL ≤2×ULN; (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; Creatinine (Cr) ≤1.5×ULN;
    3. Coagulation tests must meet the following criteria: (PT), activated partial thromboplastin time (APTT), and international normalized ratio (INR) ≤1.5×ULN (for patients not on anticoagulation); for patients on anticoagulation, PT within the expected range for prescribed anticoagulants is acceptable;
    4. Cardiac echocardiography: (LVEF) ≥55%;
  10. Preoperative assessment indicates that the patient is likely to meet the surgical criteria after therapy, is able to undergo surgery as assessed by the investigator, and can receive adjuvant therapy after surgery;
  11. Non-lactating women with a negative serum or urine pregnancy test within 7 days prior to enrollment; women of must agree to use highly effective during the study and for 6 months after the last dose of study medication;
  12. Expected survival of more than 3 months;
  13. The subject voluntarily agrees to participate in this study, signs an form, and demonstrates good compliance.

Exclusion criteria

Exclusion Criteria:

  1. Patients with breast cancer;
  2. Patients with multifocal tumors (tumors involving more than one quadrant) or bilateral breast cancer;
  3. Patients with a history of prior anti-tumor treatment, such as chemotherapy, endocrine therapy, -targeted biological therapy, or previous breast surgery (excluding diagnostic for primary breast cancer);
  4. Patients who have had or currently have other malignant tumors within the past 3 years. The following two situations are exceptions and may be included: other treated by a single operation and have achieved 5 consecutive years of disease-free survival (DFS); cured carcinoma in situ of the cervix, non-melanoma skin cancers, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invades lamina propria)];
  5. Patients currently receiving treatment in other clinical studies (except those in overall survival follow-up in another study);
  6. Patients who received major surgery, incisional biopsy, or significant traumatic injury within 28 days prior to initiation of study treatment (excluding diagnostic biopsy for primary breast cancer);
  7. Patients with long-term non-healing wounds or fractures;
  8. Patients with a history of substance abuse who are unable to abstain, or those with psychiatric disorders;
  9. Subjects with any serious and/or uncontrolled diseases, including:

    1. History of hypertensive crisis or hypertensive encephalopathy, or uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg after antihypertensive treatment);
    2. History of heart failure or systolic dysfunction ( \< 55%);
    3. Myocardial ischemia or myocardial infarction of grade ≥2, arrhythmias (including male ≥450 ms, female QTc≥470 ms), and congestive heart failure of grade ≥2 ( [NYHA] classification);
    4. Angina pectoris requiring anti-anginal medication;
    5. heart valve disease;
    6. Positive screening for , , specific antitreponemal antibody, , and peripheral blood HBV DNA level exceeding the normal range;
  10. Imaging (CT or MRI) shows tumor invasion of major blood vessels, or in the investigator's judgment the tumor is highly likely to invade major vessels and cause fatal hemorrhage during the study;
  11. History of active disease requiring systemic treatment (e.g., with disease-modifying drugs, or ) within 2 years prior to study treatment initiation. Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) is not considered systemic treatment;
  12. Diagnosed with immunodeficiency or receiving systemic glucocorticoid treatment or any other form of immunosuppressive therapy (dose >10 mg/day prednisone or equivalent), and continues to use it within 2 weeks prior to first dosing;
  13. Other comorbidities that would interfere with the planned treatment, including severe pulmonary dysfunction/disease, active or uncontrolled severe infection (≥ 5.0 grade 2 infection);
  14. Allergic to any component or of the study drug(s);
  15. Participation in other anti-tumor drug clinical trials within 4 weeks prior to randomization;
  16. Pregnant or breastfeeding women, women of with a positive baseline pregnancy test, or women of childbearing age unwilling to use effective throughout the study;
  17. In the investigator's opinion, patients with concomitant diseases that seriously endanger subject safety or affect study completion, or for any other reason are deemed unsuitable for enrollment.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Active comparator
    The control group received the TCbHP regimen

    The control group received the TCbHP regimen (docetaxel, carboplatin, trastuzumab, and pertuzumab)

    Drug: The control group

  • Experimental
    Adaptive therapy of de-escalation and escalation based on imaging and molecular Analysis

    At baseline, patients receive the Nab-P+HP regimen (albumin-bound paclitaxel plus trastuzumab and pertuzumab).After one cycle of treatment (C1), ctDNA testing is performed. After two cycles of treatment , radiological evaluation is conducted. If the patient is ctDNA (-) and achieves PR, they continue with the Nab-P+HP regimen . If the patient is ctDNA (-) and non-PR, they receive the TCbHP regimen for two cycles. If the patient is ctDNA (+) and has no mutations in the PI3K/AKT/mTOR (PAM)pathway, they receive the PyroHT regimen (pyrotinib plus trastuzumab and docetaxel) for two cycles. If the patient is ctDNA (+) at baseline or after one treatment cycle and has PAM pathway mutations, they receive the EveroHT regimen (everolimus plus trastuzumab and docetaxel) for two cycles. If the patient achieves PR after C4, they continue with the regimen for another two cycles. If PR is not achieved,the patient switches to ADC or AC+H (anthracycline plus cyclophosphamide plus trastuzumab) regimen

    Drug: Adaptive therapy of de-escalation and escalation based on imaging and molecular analysis for predicting response

Interventions

  • DrugThe control group

    received the TCbHP regimen (docetaxel, carboplatin, trastuzumab, and pertuzumab)

  • DrugAdaptive therapy of de-escalation and escalation based on imaging and molecular analysis for predicting response

    At baseline, patients receive the Nab-P+HP regimen (albumin-bound paclitaxel plus trastuzumab and pertuzumab).After one cycle of treatment (C1), ctDNA testing is performed. After two cycles of treatment , radiological evaluation is conducted. If the patient is ctDNA (-) and achieves PR, they continue with the Nab-P+HP regimen . If the patient is ctDNA (-) and non-PR, they receive the TCbHP regimen for two cycles. If the patient is ctDNA (+) and has no mutations in the PI3K/AKT/mTOR (PAM)pathway, they receive the PyroHT regimen (pyrotinib plus trastuzumab and docetaxel) for two cycles. If the patient is ctDNA (+) at baseline or after one treatment cycle and has PAM pathway mutations, they receive the EveroHT regimen (everolimus plus trastuzumab and docetaxel) for two cycles. If the patient achieves PR after C4, they continue with the regimen for another two cycles. If PR is not achieved,the patient switches to ADC or AC+H (anthracycline plus cyclophosphamide plus trastuzumab) regimen

This study also gives TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., PertuzumabStudies of PertuzumabPertuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Pathological complete response rate

    the proportion of patients assessed as having a pathological complete response after surgery among all patients who underwent surgery.

    Time frame: 2 year

Secondary outcomes

  1. Objective response rate

    The proportion of patients whose tumors have shrunk to a certain standard and maintained that reduction for a period of time, including cases of CR and PR. Tumor objective response is evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

    Time frame: 2 year

  2. 3-year EFS rate

    3-year event-free survival rate (3-year EFS rate): defined as the survival rate of all patients who have not experienced the expected endpoint event from randomization to the third year

    Time frame: 3 year

  3. 3-year invasive disease-free survival rate

    Time frame: 3 year

  4. Breast Conservation Rate

    Time frame: 2 years

  5. Patient Report Outcomes

    Assessed using the Breast Cancer Patient-Reported Outcome (PRO) scale 1.0 (NCC-BC-A 1.0)

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2025; primary completion for Dec 2027, 25 months later.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 25 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Nov 20, 2025
StartEst.
Nov 16, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07239271
Responsible party
Ma Fei,MD (Chief Physician, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Principal investigator
First posted
Nov 20, 2025
Start date
Nov 16, 2025 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 20, 2025

Study contacts

fei ma
Contact
wangwennazi@126.com
13910217780

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion